AU2011201520B2 — Capsule Formulation Of Pirfenidone And Pharmaceutically Acceptable Excipients
Assigned to Intermune Inc · Expires 2013-04-11 · 13y expired
What this patent protects
Abstract A capsule formulation of pirfenidone is provided that includes pharmaceutically acceptable excipients. In one embodiment, this capsule formulation is capable of sustaining desirable pharmackinetic responses in a patient. Further provided are methods of treating fibrotic …
USPTO Abstract
Abstract A capsule formulation of pirfenidone is provided that includes pharmaceutically acceptable excipients. In one embodiment, this capsule formulation is capable of sustaining desirable pharmackinetic responses in a patient. Further provided are methods of treating fibrotic conditions and other cytokine-mediated disorders; by administering pirfenidone capsules of such formulation to a patient in need. WO 2007/038315 PCT1US2006/037057 0o 00 2 C) E cc CD, (Jw/6u) ueevq SUBSTITUTE SHEET (RULE 26)
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.